EGFR and head and neck squamous cell carcinoma: Thus, since MPS1 has a role in both the AKT/mTOR pathway and in the activation of Aurora B activity, we believe that a combinatorial approach targeting EGFR and MPS1 could lead to an enhanced antiproliferative effect and increased cell death, and also prevent or overcome resistance to EGFR inhibition therapy in HNSCC.